Our versatile, scalable platform is ideal for novel indications and new markets. AntoXa holds an exclusive licence to use PlantForm Corporation’s vivoXPRESS® biopharmaceutical manufacturing platform to produce countermeasures for ricin, sarin, soman and Ebola Sudan, as well as other biodefense therapeutics.
Key advantages of the vivoXPRESS® platform include:
- rapid drug development and production timelines
- high levels of drug expression
- mammalian-type glycosylation (less risk of unwanted immune reactions)
- reduced risk profiles versatility (for new product development)
- unlimited scale-up capability (to respond quickly to increased demand), and
- manufacturing costs as much as 90 per cent lower than those for mammalian cell technology systems.